Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Status:
Completed
Trial end date:
2018-09-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed
or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.